聖諾醫藥-B(02257.HK)治療凝血異常疾病藥物啟動臨床試驗
聖諾醫藥-B(02257.HK)公布,基於集團GalNAc十一因子項目STP122G的I期臨床試驗已獲得美國食品藥物管理局(美國FDA)的監管許可,並將啟動該I期臨床試驗。該十一因子項目作為凝血療法適用於廣泛的疾病適應症。
公司指出,本次研究標誌著其首次將專有的GalNAc RNAi遞送平台技術GalAhead應用於該一種siRNA候選藥物中,並對凝血異常疾病需求缺口巨大的患者群體展開臨床試驗。集團預計於今年年中完成首位志願受試者給藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.